OTCPK:CMOPF (Ireland)
Â
Registered Shares
$
69.62
+0.37 (+0.53%)
12:09 AM EST
Business Description
Cosmo Pharmaceuticals NV
NAICS : 325412
SIC : 2834
ISIN : NL0011832936
Share Class Description:
CMOPF: Registered SharesCompare
Compare
Traded in other countries / regions
COPN.SwitzerlandCOPNz.UKC43.GermanyCOPN.AustriaCMOPF.USA IPO Date
2016-11-17Description
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 91.69 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-EBITDA | 0.01 | |||||
| Interest Coverage | 22.09 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 6.18 | |||||
| Beneish M-Score | -2.89 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 6.1 | |||||
| 3-Year EBITDA Growth Rate | 34.5 | |||||
| 3-Year EPS without NRI Growth Rate | 19 | |||||
| 3-Year FCF Growth Rate | 43.1 | |||||
| 3-Year Book Growth Rate | -6.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 26.72 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 9-Day RSI | 0.03 | |||||
| 14-Day RSI | 0.5 | |||||
| 6-1 Month Momentum % | 18.75 | |||||
| 12-1 Month Momentum % | 128.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.85 | |||||
| Quick Ratio | 4.48 | |||||
| Cash Ratio | 3.52 | |||||
| Days Inventory | 218.21 | |||||
| Days Sales Outstanding | 53.59 | |||||
| Days Payable | 181.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.12 | |||||
| Dividend Payout Ratio | 0.25 | |||||
| Forward Dividend Yield % | 3.12 | |||||
| 5-Year Yield-on-Cost % | 3.12 | |||||
| 3-Year Average Share Buyback Ratio | -3.6 | |||||
| Shareholder Yield % | 19.82 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 87.46 | |||||
| Operating Margin % | 47.18 | |||||
| Net Margin % | 37.8 | |||||
| FCF Margin % | 52.69 | |||||
| ROE % | 15.49 | |||||
| ROA % | 10.84 | |||||
| ROIC % | 13.16 | |||||
| ROC (Joel Greenblatt) % | 189.63 | |||||
| ROCE % | 16.35 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 15.03 | |||||
| Forward PE Ratio | 10.49 | |||||
| PE Ratio without NRI | 15.15 | |||||
| Shiller PE Ratio | 17.94 | |||||
| PS Ratio | 4.24 | |||||
| PB Ratio | 1.56 | |||||
| Price-to-Tangible-Book | 7.77 | |||||
| Price-to-Free-Cash-Flow | 8 | |||||
| Price-to-Operating-Cash-Flow | 6.68 | |||||
| EV-to-EBIT | 10.09 | |||||
| EV-to-Forward-EBIT | 9.02 | |||||
| EV-to-EBITDA | 8.68 | |||||
| EV-to-Forward-EBITDA | 7.9 | |||||
| EV-to-Revenue | 4.92 | |||||
| EV-to-Forward-Revenue | 4.1 | |||||
| EV-to-FCF | 9.54 | |||||
| Price-to-Projected-FCF | 2.94 | |||||
| Price-to-Median-PS-Value | 0.44 | |||||
| Price-to-Graham-Number | 1.98 | |||||
| Price-to-Net-Current-Asset-Value | 17.72 | |||||
| Earnings Yield (Greenblatt) % | 9.91 | |||||
| FCF Yield % | 12.81 | |||||
| Forward Rate of Return (Yacktman) % | 21.38 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:CMOPF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cosmo Pharmaceuticals NV Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 200.214 | ||
| EPS (TTM) ($) | 4.631 | ||
| Beta | 0.34 | ||
| Volatility % | 46.96 | ||
| 14-Day RSI | 0.5 | ||
| 14-Day ATR ($) | 1.354553 | ||
| 20-Day SMA ($) | 88.655 | ||
| 12-1 Month Momentum % | 128.92 | ||
| 52-Week Range ($) | 48.7 - 95 | ||
| Shares Outstanding (Mil) | 16.05 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cosmo Pharmaceuticals NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cosmo Pharmaceuticals NV Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cosmo Pharmaceuticals NV Frequently Asked Questions
What is Cosmo Pharmaceuticals NV(CMOPF)'s stock price today?
The current price of CMOPF is $69.62. The 52 week high of CMOPF is $95.00 and 52 week low is $48.70.
When is next earnings date of Cosmo Pharmaceuticals NV(CMOPF)?
The next earnings date of Cosmo Pharmaceuticals NV(CMOPF) is .
Does Cosmo Pharmaceuticals NV(CMOPF) pay dividends? If so, how much?
The Dividend Yield %  of Cosmo Pharmaceuticals NV(CMOPF) is 3.12% (As of Today), Highest Dividend Payout Ratio of Cosmo Pharmaceuticals NV(CMOPF) was 1.1. The lowest was 0.25. And the median was 0.91. The  Forward Dividend Yield % of Cosmo Pharmaceuticals NV(CMOPF) is 3.12%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers